ライフサイエンスコーパス: inoperable

1 stenosis who are at a 'high risk' or deemed inoperable.

2 e options for patients previously considered inoperable.

3 and are found to be either inappropriate or inoperable.

4 with higher mortality, no patient subset is inoperable.

5 sample is disrupted, rendering such devices inoperable.

6 ral nerve have traditionally been considered inoperable.

7 ld be actively considered in patients deemed inoperable.

8 T) for local disease control in NMSCs deemed inoperable.

9 component typically renders the entire robot inoperable.

10 s mechanical air conditioning systems become inoperable.

11 tan in 80 patients with CTEPH adjudicated as inoperable.

12 mitral regurgitation deemed at high risk or inoperable.

13 ber 2013 and September 2014, 583 HR (65%) or inoperable (35%) patients were treated via the transfemo

14 Overall Outcome: 51 patients were inoperable, 92 were subjected to exploration and biopsy

15 polymer electrolyte membrane fuel cells are inoperable above 100 degrees C, require cumbersome humid

16 n 80 patients with metastatic, recurrent, or inoperable aBTC, of whom 38 (48%) were treated with BSC

17 tive ALCL and 14 patients with metastatic or inoperable ALK-positive IMT received crizotinib orally t

18 ent TAVR included 1559 (20%) cases that were inoperable and 6151 (80%) cases that were high-risk but

19 Right from the start of Imatinib therapy in inoperable and disseminated GIST patients, specific CT i

20 For patients who are inoperable and have chronic thromboembolic pulmonary hyp

21 d improve the cost-effectiveness of TAVR for inoperable and high-risk patients, but reductions in the

22 lls to leave the primary tumor and establish inoperable and lethal metastases remain poorly understoo

23 ary angioplasty a Class 1 recommendation for inoperable and residual chronic thromboembolic pulmonary

24 TCC tumors are generally inoperable and unresponsive to traditional chemotherapy,

25 Patients with medically inoperable and/or irresectable esophageal carcinoma, ref

26 ents treated electively, 25% were considered inoperable, and 27% were considered high risk for bypass

27 Most cases are inoperable, and biopsies to investigate SCLC biology are

28 onditions, the gravity circuit appears to be inoperable, and both upward and downward swims were obse

29 mediastinum, the patient's cancer was deemed inoperable, and he was referred for consideration of con

30 s, is recommended in patients who are deemed inoperable, and is a reasonable alternative to surgical

31 ents with liver metastases were often deemed inoperable, and medical therapy conferred only minor sur

32 to improve understanding and treat the rare, inoperable, and ultimately fatal diffuse intrinsic ponti

33 a total of 419 patients (177 from cohort B [inoperable] and 242 from cohort A [operable high-risk])

34 We enrolled patients with severe symptomatic inoperable aortic stenosis and randomly assigned (1:1) t

35 ve options for access sites in patients with inoperable aortic stenosis who are ineligible for TF TAV

36 ial than standard treatment for treatment of inoperable aortic stenosis.

37 s with far advanced disease, once considered inoperable, are now often helped substantially by valve

38 Patients were studied from the inoperable arm (cohort B) of the randomized PARTNER (Pla

39 In inoperable AS patients, TAVR substantially reduced the r

40 ncurrent retinal detachment that were deemed inoperable at the time of diagnosis.

41 selected for surgery versus SBRT (medically inoperable) at physician discretion, OS was higher in su

42 AVR) for patients who were deemed surgically inoperable BACKGROUND: Data and experience with TAVI in

43 Smoothened antagonists, in the treatment of inoperable BCC.

44 approximately 30% to 50% of these tumors are inoperable because of their localization in highly eloqu

45 ents are ineffective and some tumours remain inoperable because of their size or location.

46 e of untreated left-heart disease and deemed inoperable because of unacceptable risk for open-heart s

47 Axons of diameter below 0.1 microm become inoperable because single, spontaneously opening Na chan

48 No patients were inoperable, because all patients left the operating room

49 cuses on four subgroups (stage IV, initially inoperable, bilateral, and relapsed WT) for which intern

50 n the symptomatic treatment of patients with inoperable bowel obstruction due to peritoneal carcinoma

51 ER2-negative, metastatic or locally advanced inoperable breast cancer and an Eastern Cooperative Onco

52 ER2-negative, metastatic or locally advanced inoperable breast cancer who had relapsed or progressed

53 th available operability details were deemed inoperable by the referring urologist.

54 lly those who are deemed either high risk or inoperable by the usual surgical standards.

55 adopted as an adjunct to surgery or to treat inoperable cancer and hyperthyroidism.

56 ncer after surgery, and (3) locally advanced inoperable cancer.

57 hypoparathyroidism, and 1 (12.5%) developed inoperable cancer.

58 tic radionuclides are attractive options for inoperable cancers lacking accurate imaging methods and

59 balloon test occlusions in 44 patients with inoperable carotid cavernous aneurysms or head and neck

60 trial, patients with recurrent or advanced, inoperable cervical cancer, who were aged 18 years or ol

61 on for colorectal cancer (CRC) patients with inoperable, chemorefractory hepatic metastases.

62 stent patency and survival in patients with inoperable cholangiocarcinoma treated with Gianturco met

63 diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension

64 tudy, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension

65 A are effective in improving RV afterload in inoperable chronic thromboembolic pulmonary hypertension

66 ry angioplasty (BPA) improve hemodynamics in inoperable chronic thromboembolic pulmonary hypertension

67 as technically inoperable (TI) or clinically inoperable (CLI).

68 ranscatheter aortic valve replacement (TAVR; inoperable cohort) and surgical aortic valve replacement

69 tic Transcatheter Valves (PARTNER) II trial (inoperable cohort) with a Sapien or Sapien XT valve via

70 In the inoperable cohort, patients with LF had higher mortality

71 efits compared with standard therapy in both inoperable cohorts.

72 46 of whom had cardiomyopathy and 18 who had inoperable complex congenital heart disease, underwent c

73 ren with end-stage heart failure or complex, inoperable congenital cardiac defects.

74 scularization for the treatment of otherwise inoperable coronary artery disease has increased rather

75 heart failure, surgery for vascular disease, inoperable coronary disease, and amputation for ischemic

76 significantly improved PVR in patients with inoperable CTEPH and was well tolerated.

77 Since then, 2 additional treatments for inoperable CTEPH have become available: balloon pulmonar

78 rity and long-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hy

79 data reporting outcomes for >5 patients with inoperable CTEPH were sought.

80 rent/persistent after thromboendarterectomy (inoperable CTEPH) include pulmonary vasodilators or ball

81 For patients with inoperable CTEPH, various medical and interventional the

82 prove 6MWD and hemodynamics in patients with inoperable CTEPH.

83 y vasodilator therapy alone in patients with inoperable CTEPH.

84 ocally advanced basal-cell carcinoma who had inoperable disease or for whom surgery was inappropriate

85 patients) of the patients with metastatic or inoperable disease were still alive more than 12 y after

86 rding SEMS as sole therapy for patients with inoperable disease who have not already received, or are

87 erapeutic intervention against aggressive or inoperable disease.

88 radiation doses to be given in patients with inoperable disease.

89 available treatment options for recurrent or inoperable disease.

90 lity of life improvements than those who are inoperable due to clinical comorbidities.

91 g cancer (NSCLC); however, many patients are inoperable due to comorbid diseases.

92 ts with severe aortic stenosis may be deemed inoperable due to technical or clinical reasons.

93 ned window-of-opportunity trial, in which 35 inoperable EAC patients received first-line immune check

94 ABR) is the standard treatment for medically inoperable early-stage non-small-cell lung cancer (NSCLC

95 ies evaluating systemic therapy in medically inoperable, early-stage non-small-cell lung cancer treat

96 ABR) is the standard treatment for medically inoperable, early-stage non-small-cell lung cancer.

97 y (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC

98 For inoperable esophageal adenocarcinoma (EAC), identifying

99 ent options, the prognosis for patients with inoperable esophageal carcinoma is still poor and the re

100 enosis (AS) who were deemed too high risk or inoperable for conventional aortic valve replacement (AV

101 Of the 369 patients, 23.0% were considered inoperable for technical reasons alone; the remaining we

102 TATATE has been approved for progressive and inoperable gastroenteropancreatic neuroendocrine tumors

103 Outcomes in this medically inoperable group of mostly elderly patients with comorbi

104 ion SBRT for initial treatment of localized, inoperable HCC is not cost-effective.

105 ection (AFD) software and DSA-cTACE alone in inoperable HCC patients.

106 Thirty-eight patients with inoperable HCC underwent 1.5-T MR imaging, including DW

107 Patients with inoperable HCC, no prior systemic treatment, and Child-P

108 or response and prolongs OS in patients with inoperable HCC.

109 RT are effective local treatment options for inoperable HCC.

110 patients with recurrence or metastasis (R/M) inoperable head and neck squamous cell carcinoma (HNSCC)

111 TACE is an effective treatment for inoperable hepatic tumors, especially hypervascular tumo

112 Inoperable hepatocellular carcinoma (HCC) is treated by

113 tion (IRE) in the treatment of patients with inoperable hepatocellular carcinoma (HCC) who are inelig

114 vival and tumor response in locally advanced inoperable hepatocellular carcinoma treated with TARE.

115 Four patients with inoperable hepatocellular carcinoma were treated with a

116 analysis of our early clinical outcomes for inoperable hepatocellular carcinoma.

117 s catheter-based therapies for patients with inoperable hepatocellular carcinoma.

118 ement has become the procedure of choice for inoperable, high-risk, and many intermediate-risk patien

119 e has good efficacy for recurrent/metastatic inoperable HNSCC as second-line and above-line treatment

120 analyzed 53 cases of recurrent or metastatic inoperable HNSCC who had progressed or recurred after un

121 Seventy-nine consecutive patients with inoperable IHCC were identified and treated with definit

122 of higher doses of RT improves LC and OS in inoperable IHCC.

123 PHLs were inoperable immediately after the storm.

124 Some arteriovenous malformations considered inoperable in the past can now be successfully treated u

125 of intracellular S-100B, and this pathway is inoperable in the S-100B KO (-/-).

126 smic reticulum Ca2+ pool depletion, which is inoperable in WEHI7.2 cells, and one in response to glyc

127 anical clog formation, rendering the counter inoperable, increases markedly with reductions in the si

128 Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are in

129 This cohort study of patients with inoperable LAPC found that A-RT following multiagent ind

130 s to be a reasonable first-line treatment of inoperable, larger HCC.

131 dian survival is only 6 months in those with inoperable lesions.

132 treatment option for pediatric patients with inoperable LGG WHO grades I and II.

133 chemotherapy was conducted in patients with inoperable liver metastases from CRC who had not previou

134 iofrequency ablation (RFA) for patients with inoperable localized hepatocellular carcinoma (HCC) who

135 Markov model was developed for patients with inoperable, localized HCC who were eligible for both RFA

136 an integrated therapeutic approach to treat inoperable locally advanced breast cancer.

137 ted therapies are available in patients with inoperable locally advanced cutaneous squamous cell carc

138 f cabazitaxel in patients with metastatic or inoperable locally advanced DDLPS.

139 For patients with unresectable or inoperable locally advanced disease, the incorporation o

140 uman epidermal growth factor (HER2)-negative inoperable locally advanced or metastatic breast cancer

141 se 2 trial, patients (aged >/=18 years) with inoperable locally advanced or metastatic urothelial car

142 Patients aged >=18 years with inoperable locally recurrent or metastatic SCAC, an East

143 n radiotherapy (CIRT) holds promise to treat inoperable locally-advanced non-small cell lung carcinom

144 omen aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negati

145 ely, >80% of pancreatic cancer patients bear inoperable, locally advanced, chemoresistant tumors demo

146 , chemotherapy is the standard treatment for inoperable, locally advanced, non-metastatic pancreatic

147 y confirmed clear cell renal cell carcinoma, inoperable loco-regional or metastatic disease, no previ

148 l administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer.

149 Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor

150 priate support may have a negative impact on inoperable lung cancer patients.

151 ndomized controlled trial, 115 patients with inoperable lung cancer were randomly assigned to receive

152 metastatic disease, and seven patients with inoperable lung cancer.

153 rs) with 189 primary or metastatic medically inoperable lung cancers underwent percutaneous fluorosco

154 80 patients with peritoneal carcinomatosis, inoperable malignant digestive obstruction, and two or m

155 -radiotherapy treatment 1.5 years ago due to inoperable mass in the mid-lower pole of the left kidney

156 ollected database included 222 patients with inoperable MBO treated by PTBS with uncovered nitinol SE

157 randomized clinical trial, 55 patients with inoperable mCRC and prior stable disease after standard

158 cal memory can jointly eradicate cancers and inoperable metastases and de facto vaccinate against rec

159 l in some studies in patients with advanced, inoperable metastatic disease, its use in the perioperat

160 clinical problem, because it often involves inoperable metastatic disease.

161 n 89 patients with histologically confirmed, inoperable metastatic gastroenteropancreatic NENs underg

162 y (ICC) in patients with previously treated, inoperable/metastatic hormone receptor (HR)-positive, hu

163 Patients with inoperable/metastatic HR-positive/HER2-negative breast c

164 option for patients with previously treated, inoperable/metastatic HR-positive/HER2-negative breast c

165 ne to two prior lines of chemotherapy in the inoperable/metastatic setting were randomly assigned in

166 pic mouse Lewis lung carcinoma or clinically inoperable mouse ovarian cancer, subcutaneously delivere

167 ed the prognostic impact of (18)F-FDG PET in inoperable multifocal disease.

168 and effective alternative for patients with inoperable NMSC.

169 portant recent advances in the management of inoperable non--small cell lung cancer.

170 (SBRT) is widely used for stage I medically inoperable non-small cell lung cancer (NSCLC), yet varie

171 Eleven patients with inoperable non-small cell lung cancer underwent 2-5 thor

172 Patients with inoperable non-small cell lung cancer who received stere

173 improving the outcome for locally advanced, inoperable non-small cell lung cancer.

174 ekly carboplatin/paclitaxel chemotherapy for inoperable non-small-cell lung cancer (NSCLC).

175 Patients with locally advanced or medically inoperable non-small-cell lung cancer received three-dim

176 therapy, the mainstay of treatment for early inoperable non-small-cell lung cancer, is most commonly

177 1 y of evaluation in patients with stage III inoperable nonsmall cell lung cancer based on RECIST 1.1

178 with PE/XRT alone in patients with stage III inoperable NSCLC.

179 ons after SEMS placement as sole therapy for inoperable oesophageal cancer in a resource-limited sett

180 Therapies for inoperable oesophageal cancer include chemoradiotherapy

181 ed when SEMS are placed in all patients with inoperable oesophageal cancer, as in our study, rather t

182 SEMS effectively palliate inoperable oesophageal cancer.

183 odynamic therapy are potential therapies for inoperable or advanced pancreatic cancer.

184 oach for patients with DMS who are otherwise inoperable or at high risk for surgery.

185 ty-six percent of these patients were deemed inoperable or at high surgical risk.

186 local therapy for tumors that are surgically inoperable or difficult to treat systemically.

187 ass surgery, previous myocardial infarction, inoperable or high surgical risk or multivessel disease

188 (TAVI) is an advancing mode of treatment for inoperable or high-risk patients with aortic stenosis.

189 Despite its wide success in inoperable or high-risk surgical patients, transcatheter

190 The approach can be used to treat inoperable or incompletely removed tumors by situating i

191 ad confirmed HR+ and HER2- locally recurrent inoperable or metastatic breast cancer and had received

192 otherapy-treated HR+/HER2- locally recurrent inoperable or metastatic breast cancer.

193 atment for patients with well-differentiated inoperable or metastatic NETs and disease progression af

194 ptor radionuclide therapy is a treatment for inoperable or metastatic neuroendocrine tumors.

195 el study is being conducted in patients with inoperable or metastatic solid tumors.

196 han 20 y as a systemic treatment approach in inoperable or metastatic somatostatin receptor-positive

197 atients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer u

198 Patients with inoperable or unresectable pancreatic neuroendocrine tum

199 mic medical centers with 42 patients who had inoperable or unresectable stage II to stage III NSCLC e

200 dicine has had little to offer patients with inoperable pancreatic adenocarcinoma; thus, many patient

201 s with localized, unresectable, or medically inoperable pancreatic cancer with tumors of any size and

202 Of 55 patients who had inoperable pancreatic cancer, 23 elected gemcitabine-bas

203 erapy among patients with clinical stage II (inoperable/patient refusal of surgery) or III NSCLC (Ame

204 Inoperable patients (n = 81) had a shorter median surviv

205 he pooled outcomes for all randomly assigned inoperable patients (n=449) in PARTNER, as well, includi

206 s excellent 1-year survival in high-risk and inoperable patients is achievable and provides a benchma

207 he standard of care for severely symptomatic inoperable patients or those at high risk of noncardiova

208 In inoperable patients treated with transcatheter aortic va

209 tinum agent remains the standard of care for inoperable patients who have metastatic or recurrent dis

210 placement as the preferred therapy in HR and inoperable patients with aortic stenosis.

211 Medically inoperable patients with biopsy-proven, positron emissio

212 placebo-controlled, dose-escalating study of inoperable patients with class III or IV angina.

213 scatheter aortic valve replacement (TAVR) in inoperable patients with severe aortic stenosis remain u

214 aseline renal impairment among high-risk and inoperable patients with severe aortic stenosis undergoi

215 in better survival and functional status in inoperable patients with severe aortic stenosis with dur

216 Conclusions- Among inoperable patients with severe aortic stenosis, compare

217 TAVR is attractive in high-risk or inoperable patients with severe aortic stenosis.

218 achieved with this SBRT regimen in medically inoperable patients with stage I NSCLC.

219 485 230 (95% CI, 284 550-66 7350) high-risk/inoperable patients, 152 690 (95% CI, 73 410-263 000) in

220 ents until it became the default therapy for inoperable patients, and a recommended therapy in high-r

221 tic valve replacement for high-risk (HR) and inoperable patients, mortality at 1 year was 24% in HR a

222 rge, adjudicated registry of SAPIEN 3 HR and inoperable patients, the very low rates of important com

223 overall level of immune dysfunction in these inoperable patients.

224 y also be appropriate for highly symptomatic inoperable patients.

225 discussed, including alternative options for inoperable patients.

226 0 showed a trend towards shorter survival in inoperable patients.

227 mortality at 1 year was 24% in HR and 31% in inoperable patients.

228 be clinically improved by medical therapy in inoperable patients.

229 sting its use in patients with metastatic or inoperable pheochromocytoma and paraganglioma, has resul

230 cific-activity (131)I-MIBG for metastatic or inoperable pheochromocytoma or paraganglioma by the U.S.

231 ve treatments in patients with metastatic or inoperable pheochromocytoma or paraganglioma.

232 dren with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

233 t children with neurofibromatosis type 1 and inoperable plexiform neurofibromas benefited from long-t

234 t children with neurofibromatosis type 1 and inoperable plexiform neurofibromas had durable tumor shr

235 No approved therapies exist for inoperable plexiform neurofibromas in patients with neur

236 ith neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas received oral selumet

237 hildren who had neurofibromatosis type 1 and inoperable plexiform neurofibromas to determine the maxi

238 rofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas.

239 Thirty-five patients (16%) had multiple inoperable PM and required the HR protocol.

240 age with NF1 and progressive or symptomatic, inoperable PN.

241 inib provides benefit to adults with NF1 and inoperable PNs.

242 tinib (PD-0325901), in patients with NF1 and inoperable PNs.

243 Malignant osteolysis associated with inoperable primary bone tumors and multifocal skeletal m

244 dergone orthotopic heart transplantation for inoperable primary cardiac tumors.

245 Material/CT studies of 14 patients with inoperable primary tumors and 56 patients with metastati

246 phase III study, a total of 52 patients with inoperable progressive skin lesions from histologically

247 G) is clinically used as an antiandrogen for inoperable prostate cancer, virilizing syndromes in wome

248 -three patients with recurrent or metastatic inoperable R/M HNSCC who had progressed or recurred afte

249 The most common principal causes were inoperable retinal detachment (n = 7, 36.8%), terminal g

250 pic vitrectomy was done in them to detect an inoperable retinal detachment in 1 eye.

251 han the numbers in intermediate-, high-, and inoperable-risk cohorts.

252 Two eyes had inoperable RRD.

253 Forty-four consecutive patients with inoperable, severe aortic stenosis underwent TAO TAVR in

254 standard of care in patients with advanced, inoperable soft tissue sarcoma (STS).

255 ed therapies for patients with metastatic or inoperable SSTR-expressing NETs regardless of the grade

256 Patients with medically inoperable stage I (<=5 cm) NSCLC were randomized 2:1 to

257 The optimal treatment for medically inoperable stage I non-small-cell lung cancer (NSCLC) ha

258 tereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, bu

259 Thirty-nine patients with inoperable stage II or III NSCLC, treated with chemoradi

260 feasible and highly active in patients with inoperable stage III lung cancer.

261 rapy is standard treatment for patients with inoperable stage III non-small-cell lung cancer (NSCLC).

262 Two hundred eighty-three patients with inoperable stage III non-small-cell lung cancer were ent

263 concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer.

264 onders to radiochemotherapy in patients with inoperable stage III nonsmall cell lung cancer.

265 Patients with inoperable stage III or IV non-small-cell lung cancer an

266 (PAC) is often diagnosed at an advanced and inoperable stage, and standard systemic treatments are g

267 gnancy, is typically detected late and at an inoperable stage.

268 t of severe, symptomatic aortic stenosis and inoperable status (in 2011) and high-risk but operable s

269 , 87.3% in the HR subgroup, and 82.3% in the inoperable subgroup.

270 to patients considered to be high risk or to inoperable surgical candidates.

271 n, or for those whose tumors are considered "inoperable." Technical advances, including intraoperativ

272 l alternative for patients who are medically inoperable, technically high risk, or who decline surger

273 se for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials;

274 whether they were classified as technically inoperable (TI) or clinically inoperable (CLI).

275 the entire spectrum of operative risk, from inoperable to low-risk populations, in properly designed

276 nt (SAVR); (n = 138); and Cohort B patients (inoperable) treated by either TAVR (n = 72) or standard

277 ry may provide a viable treatment option for inoperable tumors and reduce the rate of metastatic rela

278 th nonmetastatic disease, because it renders inoperable tumors operable and increases the rates of br

279 static tumors, and implantation for treating inoperable tumors respectively.

280 RE) is a promising non-thermal treatment for inoperable tumors which uses short (50-100 mus) high vol

281 es mandates further studies in patients with inoperable tumors who will receive CTL102 and CB1954.

282 tumor initiation, especially for potentially inoperable tumors, will be beneficial to obtain an overa

283 rapy have been ineffective for patients with inoperable tumours.

284 point blockade (ICB) is an approach to treat inoperable, undruggable cancers like MPNST, but successf

285 metal complexes, this reaction has appeared inoperable with aliphatic substrates.

286 of those receiving SBRT, 95% were medically inoperable, with 5% refusing surgery.

287 xidative phosphorylation machinery, which is inoperable without proteins encoded by mitochondrial DNA